论文部分内容阅读
目的探讨氨磷汀在多西他赛(TXT)和同步放射治疗非小细胞肺癌过程中对肺癌组织细胞的保护作用。方法使用MTT方法评价在TXT和同步照射(10 Gy)体外培养的SPC-A1肺癌细胞过程中,氨磷汀对SPC-A1肺癌细胞的影响;以Lewis肺癌荷瘤鼠模型评价在TXT同步放射(10 Gy)在体Lewis肺癌过程中,氨磷汀对Lewis肺癌的影响。结果体外实验表明同步放化疗加氨磷汀组和同步放化疗组的吸光度分别相当于对照组的22.8%和24.4%,2组之间比较,经过t检验P>0.05。体内实验表明,同步放化疗加氨磷汀组和同步放化疗组在实验观察的20 d内,相同时间点2组动物的肿瘤体积没有统计学上的显著差异。结论在TXT和放疗同步治疗肺癌过程中,氨磷汀无论是对离体还是在体的肿瘤细胞没有保护作用,TXT和同步放射治疗肺癌的疗效不会因为使用氨磷汀而减弱。
Objective To investigate the protective effects of amifostine on lung cancer cells during docetaxel (TXT) and concurrent radiation therapy of non-small cell lung cancer. Methods MTT assay was used to evaluate the effect of amifostine on SPC-A1 lung cancer cells in vitro and in vivo. The Lewis lung carcinoma tumor model was used to evaluate the effect of amifostine on TXT synchrotron radiation 10 Gy) in Lewis lung carcinoma in vivo. Results The in vitro experiments showed that the absorbance of chemoradiotherapy combined with amifostine and concurrent chemoradiotherapy were 22.8% and 24.4% of that of the control group respectively. Comparing the two groups, after t test, P> 0.05. In vivo experiments show that concurrent chemoradiation plus amifostine and concurrent chemoradiation group within 20 days of experimental observation, the same time point two groups of animals tumor volume was not statistically significant difference. Conclusions Amifostine has no protective effect on tumor cells in vitro or in vivo during the concurrent treatment of lung cancer with TXT and radiotherapy. The efficacy of TXT and concurrent radiotherapy in lung cancer is not attenuated by the use of amifostine.